Purpose. Triple-negative breast cancer (TNBC) is defined by the loss of expression of ER, PR, and Her2neu expressions. The aim of this study was to examine the expression of the EGFR, CK5, and Ki-67 among triple-negative breast cancer cases and to correlate the expression of the basal markers with the clinicopathological prognostic parameters. Materials and Methods. Thirty-six female patients w...

Bilateral breast cancer incidence is appreciated to be between 0.3 to 12% and is determined either by a hereditary load associated with chromosomal instability under the effect of environmental factors, or by the evolution in a particular hormonal context which gives biological aggressiveness. We present the case of a patient, aged 38 years, clinically, imagistic and bioptic diagnosed with left...

Background and Aims Gastric cancer is the third most common cause of cancer-related mortality worldwide after lungs colorectum. Although controversial, Her2neu overexpression by immunohistochemistry usually associated with poor prognosis in patients carcinoma stomach. We conducted a prospective study to evaluate prognostic role its correlation clinical, pathologic type, stage disease. Methods A...

Mutation or amplification in the PIK3CA gene is one of most frequent somatic mutations hormone-dependent Her2neu-negative breast cancer (HR+ Her2neu- cancer) and associated with an increased risk relapse, progression death. Understanding mechanisms leading to hyperactivation PI3K-mediated signaling cascade has led a new class drugs aimed at inhibiting/suppressing it. Studies efficacy pan-PI3K i...

Editorial Targeted therapies; who detects the target? After decades in which anti-cancer drugs mainly were designed to inhibit tumor cell proliferation or to interfere with DNA integrity in order to induce apop-tosis in a very general way, we recently have been witnessing the development of a new class of anticancer drugs specifically targeted at biological properties of tumor cells. Examples a...

Patients and methods 50 women with breast cancer and a BRCA1 mutation, who presented with stage I to III breast cancer between December 2006 and April 2010 were enrolled and treated with cisplatin 75 mg/m every three weeks for four cycles, followed by mastectomy and conventional chemotherapy. Eight patients had prior chemotherapy for a previous cancer diagnosis. Three patients received prior ch...

After a long period of therapeutic stagnation, significant breakthrough in the treatment adenocarcinomas gastroesophageal junction (GEJ) and stomach (GC) is now becoming evident with implementation Her2neu-based targeted therapies (trastuzumab trastuzumab-deruxtecan) use PDL1 checkpoint inhibitors (nivolumab, pembrolizumab).The required companion diagnostics regarding Her2neu overamplification ...